1. Home
  2. RDN vs ADPT Comparison

RDN vs ADPT Comparison

Compare RDN & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Radian Group Inc.

RDN

Radian Group Inc.

HOLD

Current Price

$34.88

Market Cap

4.9B

Sector

Finance

ML Signal

HOLD

Logo Adaptive Biotechnologies Corporation

ADPT

Adaptive Biotechnologies Corporation

HOLD

Current Price

$28.52

Market Cap

4.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RDN
ADPT
Founded
1977
2009
Country
United States
United States
Employees
N/A
624
Industry
Property-Casualty Insurers
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.9B
4.6B
IPO Year
2008
2019

Fundamental Metrics

Financial Performance
Metric
RDN
ADPT
Price
$34.88
$28.52
Analyst Decision
Buy
Strong Buy
Analyst Count
6
9
Target Price
$40.67
$17.78
AVG Volume (30 Days)
903.3K
1.8M
Earning Date
05-06-2026
05-05-2026
Dividend Yield
2.73%
N/A
EPS Growth
5.61
63.89
EPS
1.74
N/A
Revenue
$1,197,084,000.00
$276,976,000.00
Revenue This Year
N/A
$3.98
Revenue Next Year
$2.66
$22.72
P/E Ratio
$20.00
N/A
Revenue Growth
N/A
54.77
52 Week Low
$31.50
$12.00
52 Week High
$41.05
$28.72

Technical Indicators

Market Signals
Indicator
RDN
ADPT
Relative Strength Index (RSI) 35.65 73.30
Support Level $31.87 $23.73
Resistance Level $37.34 N/A
Average True Range (ATR) 0.68 1.13
MACD -0.12 0.34
Stochastic Oscillator 22.87 95.95

Price Performance

Historical Comparison
RDN
ADPT

About RDN Radian Group Inc.

Radian Group Inc is engaged in mortgage and real estate services. It provides both credit-related mortgage insurance coverage and other products and services across the residential real estate and mortgage finance industries. It has one reportable segment, Mortgage Insurance, which primarily derives its revenue by providing private mortgage insurance on residential first-lien mortgage loans to mortgage lending institutions and mortgage credit investors.

About ADPT Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.

Share on Social Networks: